You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Type 2 Issues Articles
Popular Type 2 Issues Articles
Highly Recommended Type 2 Issues Articles
Send a link to this page to your friends and colleagues.
On October 17, 2006, the oral medication Januvia (sitagliptin phosphate) was granted approval by the FDA. Januvia is the first diabetes treatment approved in a new class of drugs known as DDP-4 inhibitors that enhances the body’s own ability to lower elevated blood sugar.
Manufactured by Merck and Co., Januvia is indicated for use in addition to diet and exercise to improve blood sugar levels in patients with type 2 diabetes, alone or in combination with two other commonly prescribed oral diabetes medications—metformin or a PPAR (peroxisome proliferator-activated receptor gamma) agonist, when either of these drugs alone, along with diet and exercise, don’t provide adequate blood sugar control.
According to the FDA, “Januvia prolongs the activity of proteins that increase the release of insulin after blood sugar rises, such as after a meal. Januvia does this by blocking an enzyme (dipeptidyl peptidase IV or DPP-IV), which breaks down these proteins, leading to better blood sugar control.
The most common side effects in clinical studies were upper respiratory tract infection, sore throat, and diarrhea.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.